Suramin and active analogues thereof in the treatment of hypercalcemia

US5173509A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• McClellan M. Walther · Gaithersburg, US
• Renato V. LaRocca · Sterling, US
• Charles E. Myers · Rockville, US
• Cy Stein · New City, US
• W. Marston Linehan · Bethesda, US

Key dates

• Filing date: Mar 29, 1990
• Grant date: Dec 22, 1992
• Expiry date: Mar 29, 2010

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/185
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method is disclosed for the treatment of hypercalcemia in a patient, by administering to the patient an effective amount of suramin, or an active analogue thereof, for lowering calcium plasma levels in the patient. Human data shows a single course of treatment lowers plasma calcium levels to normal for three months.